Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

NCE V versus TAXUS in Europe and Asia Pacific, in which XIENCE V demonstrated superiority in the primary endpoint of in-stent late loss at 6 months, and clinical superiority on MACE with a 71 percent reduction compared to TAXUS at one year.

SPIRIT III is a large-scale pivotal clinical trial comparing XIENCE V to TAXUS in the United States and Japan that demonstrated superiority to TAXUS in the on the study's primary endpoint of in-segment late loss at eight months with a statistically significant 50 percent reduction in late loss compared to TAXUS.

Abbott's robust post-approval program is projected to enroll over 13,000 XIENCE V patients across a variety of planned clinical trials. SPIRIT IV is a 3,690-patient continued access trial that is currently enrolling patients and will evaluate the safety and efficacy of XIENCE V for the treatment of coronary artery disease in a more complex patient population in the United States. SPIRIT V is an international clinical trial that will provide additional clinical experience with XIENCE V in approximately 3,000 patients at approximately 100 clinical sites throughout Europe, Asia, Canada and Latin America. XIENCE V SPIRIT WOMEN is the world's first drug eluting stent trial to study only women and will evaluate the characteristics of 2,000 women undergoing stent implantation as well as the performance of XIENCE V in those patients in Europe, Asia-Pacific, Canada and Latin America. XIENCE V USA is a post-approval trial planned for the US with 5,000 patients.

For images of Abbott's XIENCE V stent and other information, please visit the company's online TCT newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by c
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... FAIRFIELD, N.J., Jan. 28, 2011 The Healthcare ... of the Year" is Freda Lewis-Hall, MD, chief medical ... Dr. Lewis-Hall has held leadership roles in direct ... (Photo: http://photos.prnewswire.com/prnh/20110128/DC38263 ) ...
... 2011 TechniScan (OTC Bulletin Board: TSNI ... and commercialization of an automated 3D breast ultrasound imaging ... will present at RetailInvestorConferences.com. DATE: , February 3rd, ... This will be a live, interactive online event where ...
Cached Medicine Technology:Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 2Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 3Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 4TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2
(Date:8/21/2014)... born at a low birth weight puts black women at ... The findings may partly explain high diabetes rates among ... low birth weight, the researchers added. Their study of ... low birth weight were 13 percent more likely to develop ... The risk of diabetes was 40 percent higher in those ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... and antidepressants appears to best help people with severe ... out of five people suffering from severe depression for ... with cognitive therapy plus antidepressant medication, researchers found. ... better than drugs alone in helping people with mild ...
(Date:8/21/2014)... 2014 Transvaginal mesh lawsuits ... to move forward in the federal multidistrict litigation ... West Virginia, Bernstein Liebhard LLP reports. According to ... Court has established new stipulated evidence preservation protocols ... storage and preservation. (In re C.R. Bard Inc. ...
(Date:8/21/2014)... Seattle, WA chiropractors Dr. Lincoln Kamell ... and Massage Center have recently welcomed two new ... Lang, LMP and Mike Larios, LMP have specialized training ... and have developed their expertise working in a variety ... in a clinical environment where massage is used on ...
(Date:8/21/2014)... communities do not routinely screen women for intimate ... and public health researchers. Rural women who are ... they seek help., "Rural health care providers are ... McCall-Hosenfeld, a primary care physician and assistant professor ... College of Medicine. "However, in rural settings, it ...
Breaking Medicine News(10 mins):Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2
... , TUESDAY, Dec. 6 (HealthDay News) -- U.S. officials ... controversial, unapproved and illegally labeled HCG weight loss products from ... hormone made by the human placenta and found in the ... conjunction with an extremely low-calorie diet -- as low as ...
... legacy of innovative research and commitment to patient-centered ... University and GE Healthcare have announced the commercial ... Veo, that enables physicians to diagnose patients with ... levels. CT is an advanced form of ...
... federally funded report to compare children with special health care ... of children in the United States have a special health ... greater scope of care they require for optimal health. ... A Portrait of States and the Nation 2007, provides an ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) ... an adaptation that not only ups their "yuck" factor but ... studies find. Entomologists from North Carolina State University did ... buildings in North Carolina and New Jersey. Their analysis showed ...
... , TUESDAY, Dec. 6 (HealthDay News) -- A ... been identified by scientists, but they don,t know if people ... or other health problems. Researchers in the Netherlands studied ... and low levels of triglycerides, a type of fat that ...
... observed that only a small percentage of alcoholics develop ... alcoholic liver disease (ALD); the reason why all alcoholics ... The present study from Spain, that includes original work ... levels of glutathione-S-transferases (GST) relate to the risk of ...
Cached Medicine News:Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Notre Dame, Purdue and GE Healthcare partner on new CT technology 2Health News:Notre Dame, Purdue and GE Healthcare partner on new CT technology 3Health News:Health care, home, school differ for children with special health care needs 2Health News:Bed Bugs Can Bypass Pitfalls of Inbreeding, Studies Say 2Health News:Bed Bugs Can Bypass Pitfalls of Inbreeding, Studies Say 3Health News:Gene Mutation Helps Clear Fats From Blood, Study Finds 2
5L...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Family includes fixed-volume, adjustable-volume, and multichannel ... Eppendorf Research pro Pipette. Designed with ... high-performance pipettes have earned a worldwide ... use with original Eppendorf pipette tips, ...
10L...
Medicine Products: